Total (N = 407) | |
---|---|
Sex, n (%) | |
Female | 110 (27.0) |
Male | 297 (73.0) |
Mean age (SD), years | 61.9 (12.0) |
ECOG PS, n (%) | 370 |
0 | 110 (29.7) |
1 | 206 (55.7) |
2 | 44 (11.9) |
3 | 10 (2.7) |
Histology, n (%) | 399 |
Clear cell | 357 (89.5) |
Papillary | 21 (5.3) |
Cromophobe | 9 (2.3) |
Sarcomatoid | 4 (1.0) |
Mixed | 3 (0.8) |
Collecting Duct | 1 (0.3) |
Others | 4 (1.0) |
*Targeted treatment, n (%) | |
Sunitinib | 251 (61.7) |
Sorafenib | 62 (15.2) |
Pazopanib | 56 (13.8) |
Everolimus | 70 (17.2) |
Temsirolimus | 37 (9.1) |
Bevacizumab | 5 (1.2) |